Cubist Systematic Strategies’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Cubist Systematic Strategies’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-122,260	Closed	-$1.33M	–	4109
2023 Q2	$1.33M	Buy	122,260 +122,190	+174,557%	+$1.05M	0.01%	1784
2023 Q1	$483	Sell	70 -286	-80%	-$1.79K	﹤0.01%	3815
2022 Q4	$1.42K	Buy	+356	New	+$1.75K	﹤0.01%	4141
2022 Q3	–	Sell	-76,635	Closed	-$371K	–	4850
2022 Q2	$371K	Buy	+76,635	New	+$466K	﹤0.01%	3290
2020 Q4	–	Sell	-25,654	Closed	-$330K	–	2749
2020 Q3	$330K	Buy	+25,654	New	+$221K	﹤0.01%	1956
2020 Q1	–	Sell	-400	Closed	-$3K	–	2536
2019 Q4	$3K	Buy	+400	New	+$2.25K	﹤0.01%	2382
2019 Q3	–	Sell	-4,072	Closed	-$68K	–	2551
2019 Q2	$68K	Sell	4,072 -239	-6%	-$4.15K	﹤0.01%	2283
2019 Q1	$72K	Buy	4,311 +2,711	+169%	+$39K	﹤0.01%	2051
2018 Q4	$18K	Sell	1,600 -289	-15%	-$5.85K	﹤0.01%	1959
2018 Q3	$76K	Sell	1,889 -1,282	-40%	-$36.5K	﹤0.01%	1646
2018 Q2	$90K	Buy	+3,171	New	+$70.3K	﹤0.01%	1566
2015 Q4	–	Sell	-523	Closed	-$17K	–	1984
2015 Q3	$17K	Buy	+523	New	+$29.5K	﹤0.01%	1792

Other funds holding MRNS

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Cubist Systematic Strategies's MRNS Position: Q3 2023 in Review

Cubist Systematic Strategies sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2023, closing a stake of 122,260 shares — an estimated $1.33M sold.

Cubist Systematic Strategies first reported a position in MRNS in Q3 2015 and held it in 12 quarters. The position peaked at $1.33M in Q2 2023. 104 funds tracked by Wall St. Rank hold MRNS as of Q3 2023.

Cubist Systematic Strategies reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 122,260 Marinus Pharmaceuticals, Inc shares in Q3 2023, an estimated $1.33M.
Cubist Systematic Strategies first reported a position in Marinus Pharmaceuticals, Inc in Q3 2015 and held it in 12 quarters.
Cubist Systematic Strategies's Marinus Pharmaceuticals, Inc position peaked at $1.33M in Q2 2023.
104 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2023.

Based on Cubist Systematic Strategies's 13F filing for Q3 2023, filed 14 Nov 2023.